ASX health stocks fall but Orthocell nabs FDA approval
ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir HealthInvest 2025 …